Esperion Merger Closes with $100M CVR, New Debt, and Convertible Note Amendments
ESPR has more than doubled off its 52-week low of $1.1 on elevated volume (3.8× avg).
Summary
Esperion's acquisition by Essence Parent closed today, triggering a series of capital structure changes. A CVR agreement offers up to $100M in milestone payments, adding potential upside beyond the $3.16/share cash deal. The 5.75% convertible notes due 2030 were amended to align conversion terms with the merger, including enhanced make-whole provisions. A new loan from BioPharma Credit funds the cash consideration and replaces the 2024 credit facility, which was repaid and terminated. Following the merger, Esperion announced the transfer or voluntary withdrawal of its listing. These steps finalize the take-private and reset the company's financial obligations under new ownership.
At the time of this announcement, ESPR was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $819.5M. The 52-week trading range was $1.10 to $4.18. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.